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Summary To assess the relation between oral contraceptive (OC) use and breast cancer, we analysed data
from a case-control study conducted in Northern Italy between 1983 and 1991 on 2,309 cases below age 60
and 1,928 controls admitted to hospital for acute diseases unrelated to OC use and to any of the known or
potential risk factors for breast cancer. OC use was reported by 16% of cases and 14% of controls. The
multivariate relative risk (RR) for ever vs never use of combination OC was 1.2 (95% confidence interval (CI)
1.0- 1.4). However, there was no trend in risk with duration. The RR was elevated for very short use, but
declined to 0.8 (95% CI = 0.5-1.0) for five or more years' use. No noteworthy relationship was found for
other major measures of OC use, although RR estimates were above unity for women who had stopped use
less than 5 years before (RR = 1.5, 95% CI = 1.1-2.0), started use less than 10 years before (RR = 1.3, 95%
CI = 1.0- 1.9), started when 25 or more years old (RR = 1.4, 95% CI = 1.1-1.7), or after first birth
(RR = 1.2, 95% CI = 1.0- 1.5). No interaction was observed between OC use and family history of breast
cancer, parity and age at first birth. A separate analysis of 373 cases and 456 control below age 40 showed no
association with ever use (RR = 0.9, 95% CI = 0.6-1.2).
Although a substantial amount of epidemiological data has
been published on the oral contraceptive (OC)/breast cancer
issue, the topic is still open and of interest on account of its
major public health relevance (Doll, 1990; Mann, 1990). The
global evidence on the influence of OC use on the breast in
all age groups is largely reassuring (Prentice & Thomas,
1987; Thomas, 1988; Doll, 1990; Mann, 1990; Olsson, 1989;
Delgado-Rodriguez et al., 1991; La Vecchia, 1992), and in a
formal overview based on 16 studies and over 12,000 cases,
an overall relative risk (RR) for over use of 1.0 (95%
confidence interval (CI) = 0.9-1.1) was found (Thomas,
1988).
A positive association between OC and breast cancer has
been reported in several subgroups of women, but not always
consistently. There is convincing evidence that long-term pill
use increases the risk of breast cancer in women before age
35 or 45 (Lubin et al., 1982; Meirik et al., 1986; Miller et al.,
1989; Olsson et al., 1989; Peto, 1989; UK National Case-
Control Study Group, 1989; Delgado-Rodriguez et al., 1991;
Rushton & Jones, 1992; Ursin et al., 1992), also in the
absence of any evidence of an association in older women
(Romieu et al., 1990; McPherson et al., 1987; Kay & Hanna-
ford, 1988; Rosenberg et al., 1984; Weinstein et al., 1991).
Increased risks have also been reported for use before first
term pregnancy (Pike et al., 1981; Meirik et al., 1986;
McPherson et al., 1987), but these results are not consistent
(Vessey et al., 1982; Stadel et al., 1985; Paul et al., 1986).
OC use may become a risk factor only after a long 'latent
period', so that now we may be observing only the start of a
pill-induced breast cancer epidemic (McPherson et al., 1987).
However, this is not borne out by several studies which
found no relationship between time since first use and subse-
quent breast cancer risk (Brinton et al., 1982; Schesselman et
al., 1988; Vessey et al., 1989; Ewertz, 1992).
To provide further information on this issue, we report
here the final update of a case-control study conducted in
Northern Italy (La Vecchia et al., 1986a, 1989), in a popula-
tion with a frequency of OC use considerably lower than that
in North Europe and America, where most epidemiological
studies have been conducted.
Subjects and methods
Data were derived from a case-control study of breast
cancer, based on women admitted between January 1983 and
December 1991 to a network of teaching and general hos-
pitals in the greater Milan area, Northern Italy. On average,
less than 2% of the eligible cases and 3% of controls refused
to be interviewed. The general design of this investigation has
already been described (La Vecchia et al., 1986a,b; La Vec-
chia et al., 1989).
Trained interviewers identified and questioned cases and
controls using a structured questionnaire, including inform-
ation on personal characteristics and habits, education and
socio-economic factors, gynaecological and obstetrical data,
related medical history and history of lifetime use of OC and
female hormones for other indications, including time and
duration of each episode of use and the brand name,
whenever available.
Cases were women with histologically confirmed breast
cancer, admitted to the Obstetric and Gynecology Clinics of
the University of Milan, the National Cancer Institute and
the Ospedale Maggiore (which includes the four largest
teaching and general hospitals in the greater Milan area).
There were 2,309 incident cases below the age of 60 (median
age 48 years, range 22-59) diagnosed within the year
preceding the interview.
Controls were women residing in a comparable geographi-
cal area and admitted for acute conditions to the same
network of hospitals where cases had been identified. Women
were not included if they had been admitted for gyne-
cological, hormonal or neoplastic diseases. A total of 1,928
controls below age 60 (median age 48 years, range 18-59)
was interviewed. They were admitted to hospital for a wide
spectrum of acute diseases (37% traumas, 13% other ortho-
pedic disorders, 40% acute surgical conditions, 10% miscel-
laneous other diseases).
Data analysis Relative risks (RR) of breast cancer and
the corresponding 95% confidence intervals (CI) in relation
to OC use were estimated, after adjustment for age, by the
method described by Mantel and Haenszel (1959); for multi-
ple levels of exposure, the significance of the linear trend in
risk was assessed by the Mantel test. Unconditional multiple
logistic regression, fitted by the method of maximum likeli-
hood, was used to allow for several possible confounding
factors (Breslow & Day, 1980). The regression model includ-
ed terms for age, education, marital status, family history of
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breast cancer, age at first birth, age at menarche, age at
menopause, and, in turn, various measures of OC use.
Results
The distribution of cases and controls according to age and
major identified breast cancer risk factors is reported in
Table I. Cases were more educated, more frequently married
and less frequently multiparous. There was a direct relation
between breast cancer and younger age at menarche, older
age at first birth and at menopause, and history of breast
cancer in a-first-degree relative.
Table II shows the distribution of cases and controls ac-
cording to various aspects of OC use. Ever use was reported
by 16% of cases and 14% of controls; the corresponding
age-adjusted relative risk (RR) estimate was 1.3 (95%
Confidence Interval (CI) = 1.1-1.6). After simultaneous
allowance for major identified potential confounding factors
by multiple logistic regression, the increase in risk was of
borderline statistical significance (RR = 1.2, 95% CI = 1.0-
1.4). There was no direct relation with duration of use and
short-term users (<24 months) had the highest risk (multi-
variate RR = 1.5); the RR declined (0.8, 95% CI = 0.5-1.0)
for use lasting 5 years or longer.
In relation to time since first or last OC use, the risk was
highest among women with the shortest intervals since first
use (RR= 1.5, 95% CI= 1.1-2.0) and last use (RR= 1.3,
95% CI = 1.0-1.9). The RR estimate was of borderline
statistical significance compared to never users also after
simultaneous allowance for major identified potential con-
founding factors. The risk of breast cancer was higher in
women who had first used OC when older than 25 (RR = 1.4,
95% CI = 1.1-1.7) and after their first birth (RR = 1.2, 95%
CI = 1.0-1.5). In women below 40 years, ever OC use was
reported by 35% of cases and 33% of controls, giving an
age-adjusted RR estimate of 1.1 (95% CI = 0.7-1.3) and a
multivariate RR of 0.9 (95% CI = 0.6-1.2) for ever use. The
Table I Distribution of 2,309 cases of breast cancer and 1,928
controlsa in women younger than 60 years according to selected
variables. Milan, Italy, 1983-1991
Breast cancer Controls
No. % No. %
Age (yrs)
<35 139 6.0 245 12.7
35-39 234 10.1 213 11.1
40-44 422 18.3 279 14.5
45-49 514 22.3 369 19.1
50-54 522 22.6 421 21.8
55-59 478 20.7 401 20.8
Education (yrs)
0-6 1003 43.4 973 50.5
7-11 703 30.5 559 29.0
>12 603 26.1 396 20.5
Marital status
Ever married 2087 90.4 1638 85.0
Never married 222 9.6 290 15.0
Family history of breast cancer
No 2061 89.4 1851 96.1
Yes 245 10.6 75 3.9
Parity
0 402 17.4 410 21.2
1-3 1762 76.4 1329 69.0
>4 144 6.2 188 9.8
Age at first birth (yrs)
<25 732 38.4 764 50.4
25-29 793 41.6 525 34.6
>30 380 20.0 227 15.0
Age at menarche (yrs)
< 12 996 43.2 802 41.6
13-14 1015 44.1 820 42.6
>15 292 12.7 305 15.8
Age at menopause (yrs)
Premenopause 1426 61.8 1085 56.3
<45 181 7.8 237 12.3
45-49 302 13.1 279 14.5
>50 399 17.3 326 16.9
aFor some variables the sum of strata does not add up to the total
because of missing values.
Table II Distribution of breast cancer cases and controlsa and relative risk
estimates (95% confidence interval, CI) in women younger than 60 years according
to oral contraceptive (OC) use. Milan, Italy, 1983-1991
Breast
cancer Controls
Ever use
No 1938 1663
Yes 371 265
Duration of use (months)
<24 185 109
24-59 103 70
>60 82 84
x2, trend (significance)
Time since first use (years)
<10 125 95
10- 14 106 84
>15 140 85
Time since last use (years)
<5 97 82
5-9 105 75
>10 166 103
Age at first use (years)
<25 67 101
>25 304 164
First use in relation to first birth
Before 56 44
After 258 168
Ever used for women aged <40 years
No 243 307
Yes 130 151
Duration of use for women aged <40
<24 67 61
>24 63 89
Relative risk estimates (95% CI)
M-HJ Multivariatec
Id
1.3 (1.1-1.6)
1.7 (1.3-2.2)
1.4 (1.0-2.0)
0.8 (0.6-1.2)
1.48 (P= 0.22)
1.6 (1.2-2.1)
1.1 (0.8-1.5)
1.3 (1.0-1.8)
1.4 (1.0-2.0)
1.3 (0.9-1.7)
1.3 (1.0-1.7)
0.8 (0.6-1.1)
1.6 (1.3-1.9)
1.1 (0.7-1.7)
1.3 (1.0-1.6)
1d
1.1 (0.7-1.3)
years (months)
1.4 (0.9-2.1)
0.9 (0.6-1.3)
1.2 (1.0-1.4)
1.5 (1.2-2.0)
1.3 (0.9-1.8)
0.8 (0.5-1.0)
0.0024 (P = 0.96)
1.5 (1.1-2.0)
1.0 (0.7-1.4)
1.2 (0.9-1.6)
1.3
1.1
1.2
(1.0- 1.9)
(0.8-1.6)
(0.9-1.5)
0.7 (0.5-1.1)
1.4 (1.1-1.7)
0.9 (0.6-1.3)
1.2 (1.0-1.5)
1d
0.9 (0.6-1.2)
1.2 (0.8-1.9)
0.9 (0.6-1.3)
aFor some variables the sum of strata does not add up to the total because of
missing values. bMantel-Haenszel estimates adjusted for age. cEstimates from
multiple logistic regression; allowance was made for age, education, marital status,
family history of breast cancer, age at menarche and menopause, parity, age at
first birth, and, in turn, OC use, duration of use, time since first and last use, age
at first use and first use in relation to birth. dReference category.570 A. TAVANI et al.
Table III Interaction between oral contraceptive (OC) use with
family history of breast cancer, parity and age at first birth on the
risk of breast cancer. Milan, Italy, 1983-1991
Relative risk estimates (95% CI)a
OC use
Neverb Ever
Family history of breast cancer
No 1 1.3 (1.1-1.6)
[1728:1595] [333:256]
Yes 1 1.6 (0.7-3.5)
[210:68] [38:9]
Parity
Nulliparae 1 1.5 (1.0-2.4)
[338:347] [64:62]
Parae 1 1.3 (1.1-1.6)
[1600:1316] [307:203]
Age at first birth
<25 1 1.1 (0.8-1.5)
[618:648] [114:116]
>25 1 1.5 (1.1-2.0)
[982:668] [193:86]
aNumber in square brackets are the case:controls in each category.
bReference category.
risk estimate was not elevated also for two or more years of
use (RR = 0.9, 95% CI = 0.6-1.3). The interaction between
OC use and parity, age at first birth and family history of
breast cancer is considered in Table III. The risk estimates
were similar in various strata of covariates considered, and
no significant interaction was observed.
Discussion
The final results of this study indicate that in women below
60 years there was no relationship between duration of OC
use and breast cancer risk and, indeed, the risk tended to
decrease with longer exposure. In women below 40 years,
who had a higher prevalence of use than those aged 40 to 59,
the RR estimates for ever use were not significant. However,
although large, this study included only 56 cases and 44
controls who used OC before first pregnancy, 67 cases and
101 controls before age 25, 140 cases and 85 controls starting
use 15 or more years before diagnosis, and 166 cases and 103
controls stopping use 10 or more years before diagnosis; thus
it provides only limited information to several questions
currently causing concern (Mann, 1990).
Allowance for major identified confounding factors led to
a small, but systematic decrease in the RR estimates, sugges-
ting that some residual confounding by social class or other
covariates may still be present and might explain the increase
in risk observed for shorter duration of use, for starting use
after 25 years and after first birth. A potential residual
confounding factor may be the presence of benign breast
disease, which is inversely related to OC use, but directly
associated with breast cancer risk (La Vecchia, 1984). Benign
breast disease could also at least in part, underlie the incon-
sistency observed in the relationship between breast cancer
risk and duration, latency and recency of OC use.
Information or recall bias may also be a plausible explana-
tion of the increased risk for short duration of use: short-
term or use a long time ago might have been reported more
carefully by cases than controls (Skegg, 1988). Thus, the
apparently elevated risk estimates in these subgroups should
be viewed with extreme caution.
The RR estimates slightly above unity for short time since
first and last OC use may be explained within the framework
of a multistage process of breast carcinogenesis, in terms of a
late stage (promotional) effect (Day & Brown, 1980). This
resembles the transient increase in the risk of breast cancer
found after a full-term pregnancy (Bruzzi et al., 1988; La
Vecchia et al., 1990).
These findings are not in agreement with most previous
evidence referring to the pattern of risk in younger women
(<40 years) (Lubin et al., 1982; Meirik et al., 1986; McPher-
son et al., 1987; Kay & Hannaford, 1988; Miller et al., 1989;
Olsson et al., 1989; Peto, 1989; UK National Case-Control
Study Group, 1989; Romieu et al., 1990; Delgado-Rodriguez
et al., 1991; Weinstein et al., 1991; Rushton & Jones, 1992;
Ursin et al., 1992), and in those who used OC at a younger
age or before first birth (Pike et al., 1981; Meirik et al., 1986;
McPherson et al., 1987). Since the confidence intervals of
these estimates are wide, chance by itself is a plausible inter-
pretation.
The possibility of bias must also be considered. Possibly
the results of this study reflect the different pattern ofOC use
among Italian women, characterised by extremely infrequent
(and probably highly selective) use in the older generations
(i.e. among women above age 30 in the 1970s and 1980s) (La
Vecchia et al., 1986b). Although the low prevalence of OC
use causes major difficulties in relation to study power and
possibly also to selective mechanisms, the sample size of this
study, based on over 2,300 cases and 1,900 controls, provides
reasonably stable risk estimates in a population whose pat-
terns of pill use differ substantially from Northern Europe or
the USA (Thomas, 1988; Romieu et al., 1990).
Another potential limitation of this study is its hospital-
based design, with all the consequent implications, such as
the use of hospital controls, which can be open to debate
(Mantel & Haenszel, 1959). The results, however, could not
be explained in terms of selection or confounding bias, since
the catchment areas of cases and controls were well com-
parable, participation was almost complete, and allowance
for several confounding factors only slightly modified the
relative risk estimates. Further, the hospital setting may well
improve recall of past drug use, particularly in controls,
although this cannot totally eliminate a potential better recall
by breast cancer cases, particularly for short term use in the
distant past (Skegg, 1988).
In conclusion, the low prevalence of OC use in this Italian
population seriously hampered analysis, and particularly any
inference on subgroups, time factors, dose or type of
preparation. Nevertheless, the large size of the dataset, the
originality of the population, in terms of baseline breast
cancer incidence and patterns of hormone use (La Vecchia et
al., 1986b), and the consistency of its results with the overall
evidence from other studies (Mann, 1990) add useful inform-
ation to a debate of major public health relevance. The
indications emerging from this study for the use of OC and
the risk of breast cancer are reassuring and should help in
assessing the pattern of breast cancer risk better for various
time-related factors of OC use in a Southern European
population.
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